Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | PGR | P06401 | 12/20 | 0.61 |
| ▸ | B3GNT2 | Q9NY97 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793653 | 0.86 | POLB (0.62) | MAOBPOLBPGR | |
| SCHEMBL22419394 | 0.86 | MAOB (0.57) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL12026657 | 0.83 | LMNA (0.53) | MAOBPOLBPGR | |
| SCHEMBL2975327 | 0.83 | POLB (0.62) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL2968866 | 0.81 | PGR (0.72) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL20987129 | 0.81 | PGR (0.60) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL2970468 | 0.81 | PGR (0.78) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL29414802 | 0.81 | PGR (0.60) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL29464129 | 0.81 | PGR (0.78) | MAOBPOLBPGRB3GNT2 | |
| SCHEMBL22157046 | 0.81 | MAOB (0.53) | MAOBPOLBPGRB3GNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2021-06-17 | — | — | US | disclosed |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2020-09-15 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10363257-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-07-30 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | MAOB 3305/4885POLB 385/4885PGR 3140/4885 |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | MAOB 3305/4885POLB 385/4885PGR 3140/4885 |
| US-10772892-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | MAOB 3305/4885POLB 385/4885PGR 3140/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MAOB 3934/4885POLB 413/4885PGR 3258/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | MAOB 3601/4885POLB 2323/4885PGR 2823/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MAOB 3934/4885POLB 413/4885PGR 3258/4885 |
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MAOB 3934/4885POLB 413/4885PGR 3258/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MAOB 3934/4885POLB 413/4885PGR 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.